Top Markets
#1 Siren Siren +44.16%
#2 Seeker Seeker +32.30%
#3 Full Moon Full Moon +19.18%
#4 Zora Zora +17.31%
#5 Wrapped NXM Wrapped NXM +12.17%
#6 VVS Finance VVS Finance +10.82%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +10.49%
#8 Cryptopia Cryptopia +9.12%
#9 Axelar Axelar +8.99%
#10 0G 0G +8.98%
Coin of the day
Siren Siren
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Silence Therapeutics plc Silence Therapeutics plc

Silence Therapeutics plc

SLN
Classement en actions #12014
Silence Therapeutics plc is a London, UK-based biotechnology company... Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
Prix de l'action
$13.34
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$629.93M
Changement (1 jour)
-0.84%
Changement (1 an)
177.26%
Pays
GB
Échange Silence Therapeutics plc (SLN)

Catégorie

Healthcare
Nombre d'actions en circulation pour Silence Therapeutics plc (SLN)
Nombre d'actions en circulation au August 2026: 0
Selon les derniers rapports financiers et le cours de l'action de Silence Therapeutics plc, le nombre actuel d'actions en circulation est de 0. À la fin de August 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Silence Therapeutics plc (SLN) de 2026 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
Pas assez de données pour les dates fournies.
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH